These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 9799755)

  • 1. Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen.
    Rosenquist C; Fledelius C; Christgau S; Pedersen BJ; Bonde M; Qvist P; Christiansen C
    Clin Chem; 1998 Nov; 44(11):2281-9. PubMed ID: 9799755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides.
    Christgau S; Rosenquist C; Alexandersen P; Bjarnason NH; Ravn P; Fledelius C; Herling C; Qvist P; Christiansen C
    Clin Chem; 1998 Nov; 44(11):2290-300. PubMed ID: 9799756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a monoclonal antibody to urinary degradation products from the C-terminal telopeptide alpha 1 chain of type I collagen. Application in an enzyme immunoassay and comparison to CrossLaps ELISA.
    Fledelius C; Kolding I; Qvist P; Bonde M; Hassager C; Reginster JY; Hejgaard J; Frøokiaer H; Christiansen C
    Scand J Clin Lab Invest; 1997 Feb; 57(1):73-83. PubMed ID: 9127460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evaluation of the Elecsys beta-CrossLaps serum assay, a new assay for degradation products of type I collagen C-tlopeptides.
    Okabe R; Nakatsuka K; Inaba M; Miki T; Naka H; Masaki H; Moriguchi A; Nishizawa Y
    Clin Chem; 2001 Aug; 47(8):1410-4. PubMed ID: 11468230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen.
    Bonde M; Garnero P; Fledelius C; Qvist P; Delmas PD; Christiansen C
    J Bone Miner Res; 1997 Jul; 12(7):1028-34. PubMed ID: 9200001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new monoclonal antibody ELISA for detection and characterization of C-telopeptide fragments of type I collagen in urine.
    Srivastava AK; MacFarlane G; Srivastava VP; Mohan S; Baylink DJ
    Calcif Tissue Int; 2001 Dec; 69(6):327-36. PubMed ID: 11800229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coated-tube radioimmunoassay for C-telopeptides of type I collagen to assess bone resorption.
    Bonde M; Fledelius C; Qvist P; Christiansen C
    Clin Chem; 1996 Oct; 42(10):1639-44. PubMed ID: 8855148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption.
    Clemens JD; Herrick MV; Singer FR; Eyre DR
    Clin Chem; 1997 Nov; 43(11):2058-63. PubMed ID: 9365389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the menopause and hormone replacement therapy on the carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen.
    Hassager C; Risteli J; Risteli L; Christiansen C
    Osteoporos Int; 1994 Nov; 4(6):349-52. PubMed ID: 7696831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma.
    Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Biondi B; Iorio S; Giustina A; Amato G; Carella C
    J Bone Miner Res; 2005 Mar; 20(3):480-6. PubMed ID: 15746993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Markers of bone resorption--measurement in serum, plasma or urine?
    Huber F; Traber L; Roth HJ; Heckel V; Schmidt-Gayk H
    Clin Lab; 2003; 49(5-6):203-7. PubMed ID: 15285175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of serum and urinary C-terminal telopeptide of type I collagen in aging, menopause and osteoporosis.
    Kawana K; Takahashi M; Hoshino H; Kushida K
    Clin Chim Acta; 2002 Feb; 316(1-2):109-15. PubMed ID: 11750280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the clinical performance of the immunoenzymometric assays for N-terminal and C-terminal type I collagen telopeptides and the HPLC assay for pyridinium cross-links.
    Bettica P; Masino M; Cucinotta E; Vago T; Norbiato G; Moro L; Suarez KN; Romanello M; Bevilacqua M
    Eur J Clin Chem Clin Biochem; 1997 Jan; 35(1):63-8. PubMed ID: 9156570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women.
    Chaki O; Yoshikata I; Kikuchi R; Nakayama M; Uchiyama Y; Hirahara F; Gorai I
    J Bone Miner Res; 2000 Aug; 15(8):1537-44. PubMed ID: 10934652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of methods for measuring serum and urinary markers of bone metabolism in cats.
    DeLaurier A; Jackson B; Pfeiffer D; Ingham K; Horton MA; Price JS
    Res Vet Sci; 2004 Aug; 77(1):29-39. PubMed ID: 15120950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and application of a serum C-telopeptide and osteocalcin assay to measure bone turnover in an ovariectomized rat model.
    Srivastava AK; Bhattacharyya S; Castillo G; Wergedal J; Mohan S; Baylink DJ
    Calcif Tissue Int; 2000 Jun; 66(6):435-42. PubMed ID: 10821880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy.
    Christgau S; Bitsch-Jensen O; Hanover Bjarnason N; Gamwell Henriksen E; Qvist P; Alexandersen P; Bang Henriksen D
    Bone; 2000 May; 26(5):505-11. PubMed ID: 10773591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine.
    Hanson DA; Weis MA; Bollen AM; Maslan SL; Singer FR; Eyre DR
    J Bone Miner Res; 1992 Nov; 7(11):1251-8. PubMed ID: 1466251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies.
    Rosenquist C; Qvist P; Bjarnason N; Christiansen C
    Clin Chem; 1995 Oct; 41(10):1439-45. PubMed ID: 7586514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Markers of bone turnover in postmenopausal women receiving hormone replacement therapy.
    Hamwi A; Ganem AH; Grebe C; Kerschan-Schindl K; Preisinger E; Boschitsch E; Bieglmayer C
    Clin Chem Lab Med; 2001 May; 39(5):414-7. PubMed ID: 11434391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.